Global Ocular inflammation treatment market analysis and forecast (2019-2026) by offering classification (Anterior uveitis, Intermediate uveitis, Pan- Uveitis, Posterior uveitis), Path physiology, Epidemiology, Treatment (Analgesics, Antibodies, Antifungal, Antiviral, Corticosteroids, Cycloplegic agent, Immunosuppressant, Monoclonal antibodies), Geology (North America, Latin America, Europe, Asia Pacific (APAC), Middle East and Africa, Rest of APAC)

Global Ocular inflammation treatment market analysis and forecast (2019-2026) by offering classification (Anterior uveitis, Intermediate uveitis, Pan- Uveitis, Posterior uveitis), Path physiology, Epidemiology, Treatment (Analgesics, Antibodies, Antifungal, Antiviral, Corticosteroids, Cycloplegic agent, Immunosuppressant, Monoclonal antibodies), Geology (North America, Latin America, Europe, Asia Pacific (APAC), Middle East and Africa, Rest of APAC)

Market Scenario

Global Ocular Inflammation Treatment Market is expected to reach at 28.68 USD in 2018 to XX USD in 2026 at XX % CAGR.   This is a comprehensive report analyzing the current ocular inflammation treatment market. The word uvea (referring to grape or grape-like), also called uveal layer or vascular tunic is the pigmented in middle of the three concentric layers that make a human eye. An inflamed ocular is a condition when uvea turns swollen, red and painful. This condition causes irritations, burning, redness, blurred vision, sensitivity to light, irregularly shaped pupil, dark spots in vision basically and in worst cases, it causes permanent blindness. The very often cases of diseases and complexity of diseases have put the treatment market in the key position. According to the survey published in JAMA ophthalmology non-infected uveities in children has reported 29 per 100,000 cases and in adults, the rate is 121 per 100,000 cases in the year of 2016. This study has done to provide information about the global ocular inflammation treatment market, related market and hence to show opportunities, major global revenue makers in this field. Ocular inflammation treatment market by region: In average age of 20 to 60 years (both male and female) approximately 10 out of 45000 people suffers from uveitis. 1. North America 2.  Latin America 3. Europe 4. Asia Pacific (APAC) 5. Middle East and Africa (MEA) Ocular inflammation treatment market by anatomical classification On the basis of the parts of eyes affected in an early stage of inflammation, the disease is referred to as: • Anterior uveitis • Intermediate uveitis • Posterior uveitis • Pan- uveitis or Diffuse uveitis Ocular inflammation treatment market by treatment type: Uveities is usually treated by glucocorticoid steroids given to patient orally or through eye drops. A successful treatment of uveities is increasing T-regulatory cells which help in reducing inflammation in the eye. • Analgesics • Antibodies • Antifungal • Antiviral • Corticosteroids • Cycloplegic agents • Immunosuppressant • Monoclonal antibodies Ocular inflammation treatment market by causes : Uveitis can have many causes, including external injury and inflammatory diseases. Exposure to toxic chemicals such as pesticides and acids used in manufacturing processes also can cause uveitis. Where else it can be caused by the inside of eye due to some infection. The type of uveitis you have is classified by where inflammation occurs in the uvea: • Infectious • Non-infectious • Systemic disorders • Side effect of drug Widely administrated vaccines are reported to cause uveities majorly: • White dot syndrome When inflammation causes are unknown but it is confined to eyes only, in this cases it is defined as White dot syndrome. • Masquerade syndrome This condition is when immune-uveities are not responsible for the presence of intraocular cells. Ocular inflammation treatment market by Pathophysiology • Immunological factor • Infectious factor • Genetic factor Ocular inflammation treatment market by a channel of distribution • Online channel • Retail pharmacies • Hospital pharmacies • Small drug stores • Home delivery Key players: •  AbbVie Inc. • Alimera Sciences Inc. • Allergan Inc. • Bausch & Lomb Incorporated. • Eyegate • Eyegate Pharmaceuticals Inc. • Novartis AG (Alcon Laboratories Inc.) • pSivida Corp. •  Regeneron Pharmaceuticals Inc. • Santen Pharmaceutical Co. Ltd. • Valeant Pharmaceuticals International Inc. • Akorn Pvt. Ltd • Roche Ltd • Senju Pharmaceutical Co. Ltd • Bayer HealthCare Pharmaceutical LLC • Pfizer Pharmaceutical company Key highlights • This report contains assessment of potential revenue opportunities across different segments and explains the investment proposition matrix for this market • The market drivers, restraints, opportunities, new product developers, regional players and strategy adopted by the leading players is made clear through this report. • It profiles detail study of key players in the global uveitis treatment market based on company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies and future plans • Key companies covered as a part of this study include AbbVie Inc. Alimera Sciences Inc., Allergan Inc., Bausch & Lomb Incorporated., Eyegate Pharmaceuticals Inc., Novartis AG (Alcon Laboratories Inc.), pSivida Corp., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Valeant Pharmaceuticals International Inc., Akorn Pvt. Ltd, Roche Ltd, Senju Pharmaceutical Co. Ltd, Bayer HealthCare, Pharmaceutical LLC, Pfizer Pharmaceutical company • Insights from this report would allow investor and the management authorities to make an informed decision regarding their future product launch, technology, market expansion, and marketing. The scope of the report: By using survey and sub survey’s reliable data on global ocular inflammation treatment market by a number of population suffering from diseases and various sectors or businesses of this market the research report shows possibilities in the field of uveities treatment. Global Medical Imaging Market

Table of Contents

1. EXECUTIVE SUMMARY 2. RESEARCH METHODOLOGY 2.1. Market Definition 2.2. Market Scope 2.3. Data Sources 3. MARKET VARIABLES & SCOPE 3.1. Market Segmentation & Scope 3.2. Market Driver Analysis 3.3. Market Restraint Analysis 3.4. Penetration &Growth Prospect Mapping 3.5. Market SWOT Analysis, By Factor (political & legal, economic and technological) 3.6. Porter’s Five Forces Industry Analysis 3.7. Market Value Chain Analysis 4. Ocular inflammation treatment market by region 4.1. Introduction 4.2. North America 4.3. Latin America 4.3.1.1. Brazil 4.3.1.2. Argentina 4.3.1.3. Rest of Latin America 4.4. Europe 4.4.1.1. Russia 4.5. Asia Pacific (APAC) 4.6. Middle East and Africa (MEA) 4.6.1.1. GCC Countries 4.6.1.2. Israel 4.6.1.3. Rest of Middle-east and Africa 4.7. Rest of APAC 5. Ocular inflammation treatment market by types of diseases 5.1. Introduction 5.2. Anterior uveitis 5.3. Intermediate uveitis 5.4. Posterior uveitis 5.5. Pan- uveitis or Diffuse uveitis 6. Ocular inflammation treatment market by treatment type 6.1. Introduction 6.2. Analgesics 6.3. Antibodies 6.4. Antifungal 6.5. Antiviral 6.6. Corticosteroids 6.7. Cycloplegic agents 6.8. Immunosuppressant 6.9. Monoclonal antibodies 7. Ocular inflammation treatment market by causes 7.1. Introduction 7.2. Infectious 7.3. Non-infectious 7.4. Systemic diseases 7.5. Side effect of drug 7.6. White dot syndrome 7.7. Masquerade syndrome 7.7.1.1. Neoplastic 7.7.1.2. Non-neoplastic 8. Ocular inflammation treatment market by distribution of drugs 8.1. Introduction 8.2. Online channel 8.3. Retail pharmacies 8.4. Hospital pharmacies 8.5. Small drug stores 8.6. Home delivery 9. Ocular inflammation treatment market by key players 9.1. Introduction 9.2. AbbVie Inc. 9.2.1.1. By diseases type 9.2.1.1.1.1. Global market share 9.2.1.1.1.2. Region of operation 9.2.1.2. By treatment type 9.2.1.2.1.1. Global market share 9.2.1.2.1.2. Area of operation 9.3. Alimera Sciences Inc. 9.3.1.1. By diseases type 9.3.1.1.1.1. Global market share 9.3.1.1.1.2. Region of operation 9.3.1.2. By treatment type 9.3.1.2.1.1. Global market share 9.3.1.2.1.2. Region of operation 9.4. Allergan Inc. 9.4.1.1. By diseases type 9.4.1.1.1.1. Global market share 9.4.1.1.1.2. Region of operation 9.4.1.2. By treatment type 9.4.1.2.1.1. Global market share 9.4.1.2.1.2. Region of operation 9.5. Bausch & Lomb Incorporated. 9.5.1.1. By diseases type 9.5.1.1.1.1. Global market share 9.5.1.1.1.2. Region of operation 9.5.1.2. By treatment type 9.5.1.2.1.1. Global market share 9.5.1.2.1.2. Area of operation 9.6. Eyegate Pharmaceuticals Inc. 9.6.1.1. By diseases type 9.6.1.1.1.1. Global market share 9.6.1.1.1.2. Region of operation 9.6.1.2. By treatment type 9.6.1.2.1.1. Global market share 9.6.1.2.1.2. Area of operation 9.7. Novartis AG (Alcon Laboratories Inc.) 9.7.1.1. By diseases type 9.7.1.1.1.1. Global market share 9.7.1.1.1.2. Region of operation 9.7.1.2. By treatment type 9.7.1.2.1.1. Global market share 9.7.1.2.1.2. Area of operation 9.8. pSivida Corp. 9.8.1.1. By diseases type 9.8.1.1.1.1. Global market share 9.8.1.1.1.2. Region of operation 9.8.1.2. By treatment type 9.8.1.2.1.1. Global market share 9.8.1.2.1.2. Area of operation 9.9. Regeneron Pharmaceuticals Inc. 9.9.1.1. By diseases type 9.9.1.1.1.1. Global market share 9.9.1.1.1.2. Region of operation 9.9.1.2. By treatment type 9.9.1.2.1.1. Global market share 9.9.1.2.1.2. Area of operation 9.10. Santen Pharmaceutical Co. Ltd. 9.10.1.1. By diseases type 9.10.1.1.1.1. Global market share 9.10.1.1.1.2. Region of operation 9.10.1.2. By treatment type 9.10.1.2.1.1. Global market share 9.10.1.2.1.2. Area of operation 9.11. Valeant Pharmaceuticals International Inc. 9.11.1.1. By diseases type 9.11.1.1.1.1. Global market share 9.11.1.1.1.2. Region of operation 9.11.1.2. By treatment type 9.11.1.2.1.1. Global market share 9.11.1.2.1.2. Area of operation 9.12. Akorn Pvt. Ltd 9.12.1.1. By diseases type 9.12.1.1.1.1. Global market share 9.12.1.1.1.2. Region of operation 9.12.1.2. By treatment type 9.12.1.2.1.1. Global market share 9.12.1.2.1.2. Area of operation 9.13. Roche Ltd 9.13.1.1. By diseases type 9.13.1.1.1.1. Global market share 9.13.1.1.1.2. Region of operation 9.13.1.2. By treatment type 9.13.1.2.1.1. Global market share 9.13.1.2.1.2. Area of operation 9.14. Senju Pharmaceutical Co. Ltd 9.14.1.1. By diseases type 9.14.1.1.1.1. Global market share 9.14.1.1.1.2. Region of operation 9.14.1.2. By treatment type 9.14.1.2.1.1. Global market share 9.14.1.2.1.2. Area of operation 9.15. Bayer HealthCare Pharmaceutical LLC 9.15.1.1. By diseases type 9.15.1.1.1.1. Global market share 9.15.1.1.1.2. Region of operation 9.15.1.2. By treatment type 9.15.1.2.1.1. Global market share 9.15.1.2.1.2. Area of operation 9.16. Pfizer Pharmaceutical company 9.16.1.1. By diseases type 9.16.1.1.1.1. Global market share 9.16.1.1.1.2. Region of operation 9.16.1.2. By treatment type 9.16.1.2.1.1. Global market share 9.16.1.2.1.2. Area of operation

About This Report

Report ID3170
Category Healthcare
Published DateAugust 2019
No of Pages178
Contact Us
Call Now